Large gap with delayed quotes
|
Last quote
10/16/2025
-
02:00:00
|
Bid
10/16/2025 -
14:03:43
|
Bid Volume |
Ask
10/16/2025 -
14:03:43
|
Ask Volume |
|---|---|---|---|---|
|
576.42
+3.82
(
+0.67% )
|
520.07
|
100 |
635.01
|
100 |
Analysis date: 14.10.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 07.10.2025.
Interest
Strong
Strong
Three stars since 14.10.2025.
Earnings Rev Trend
-0.10
-0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 03.10.2025 at a price of 600.00.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 04.07.2025.
4wk Rel Perf
1.34%
1.34%
The four-week dividend-adjusted overperformance versus SP500 is 1.34%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 07.10.2025.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.36%.
Mkt Cap in $bn
59.11
59.11
With a market capitalization >$8bn, REGENERON PHARMA is considered a large-cap stock.
G/PE Ratio
0.90
0.90
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
11.77
11.77
The estimated PE is for the year 2027.
LT Growth
10.00%
10.00%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
20
20
Over the last seven weeks, an average of 20 analysts provided earnings per share estimates.
Dividend Yield
0.65%
0.65%
The twelve month estimated dividend yield represents 7.62% of earnings forecasts.
Beta
58
58
For 1% of index variation, the stock varies on average by 0.58%.
Correlation
0.30
0.30
Stock movements are strongly independent of index variations.
Value at Risk
183.61
183.61
The value at risk is estimated at USD 183.61. The risk is therefore 32.07%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
02.04.2004
02.04.2004